Brand & Product Security

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect patients from unapproved compounded semaglutide products by targeting pharmacies, telehealth providers, and deceptive marketing practices that compromise safety, mislead consumers, and violate FDA regulations.

Novo Nordisk Ramps Up Legal Fight Against Compounded Semaglutide Knockoffs

Videos

In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, discusses how the pharmaceutical industry is balancing high-cost innovation, especially in obesity and metabolic disease, with payer demands for cost containment, highlighting the growing role of biosimilars and future generics in offsetting spend.

How Pharma Can Navigate Innovation and Cost Pressures in the GLP-1 Era

In the fourth part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.

Pharma Industry Shifts Toward Full Activation

The letters demand US drug prices match or undercut global lows, triggering a 60-day compliance timeline, and prompting strategic responses from players in the space, including Celltrion.


Trump’s MFN Drug Pricing Push Targets 17 Big Pharma Companies, Spurs Global Industry Response

In the third part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.

Balancing Compliance and Supply Chain Continuity

Is the industry ready for the Aug. 1 deadline of when these levies go into effect?

As Trump Pharma Tariff Deadline Looms, Here's How the Sector Got Here

In the final part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, discusses the potential repercussions of telehealth companies selling GLP-1s.

Weighing Cost Savings Against Safety and Regulatory Risks

The new deal imposes 15% tariffs on most EU exports, including pharmaceuticals.

United States, European Union Reach Trade Pact

Kevin Chinn, vice president and head of the cell & gene therapy service line at Cencora, outlines why early planning, stakeholder engagement, and innovative access strategies are key to long-term CGT success.

How CGT Developers Can Overcome Market Access, Regulatory, and Commercialization Hurdles

In the fifth part of this roundtable discussion, a panel of KOLs explore how the chain of custody and chain of ownership are impacted by supply chain challenges, such as last-mile distribution and DSCSA data security. 

Legal & Regulatory